Search Results - "Herrlinger, K."

Short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – experience in 130 patients by Schmidt, K. J., Herrlinger, K. R., Emmrich, J., Barthel, D., Koc, H., Lehnert, H., Stange, E. F., Fellermann, K., Büning, J.

“…Summary Background Steroid‐refractory ulcerative colitis (UC) remains a challenging condition warranting surgery upon failure of pharmacological treatment…”
Get full text

NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression by Wehkamp, J, Harder, J, Weichenthal, M, Schwab, M, Schäffeler, E, Schlee, M, Herrlinger, K R, Stallmach, A, Noack, F, Fritz, P, Schröder, J M, Bevins, C L, Fellermann, K, Stange, E F

“…Background: Mutations in NOD2, a putative intracellular receptor for bacterial peptidoglycans, are associated with a subset of Crohn’s disease but the…”
Get full text

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus by HERRLINGER, K. R., BARTHEL, D. N., SCHMIDT, K. J., BÜNING, J., BARTHEL, C. S., WEHKAMP, J., STANGE, E. F., FELLERMANN, K.

“…Aliment Pharmacol Ther 31, 1036–1041 Summary Background  The calcineurin inhibitor tacrolimus and the anti‐TNF‐antibody infliximab are established options in…”
Get full text

ABCB1 Single‐Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis by Herrlinger, KR, Koc, H, Winter, S, Teml, A, Stange, EF, Fellermann, K, Fritz, P, Schwab, M, Schaeffeler, E

“…Tacrolimus (Tac) is effective in the treatment of steroid‐refractory ulcerative colitis (UC); however, nonresponse and unpredictable side effects are major…”
Get full text

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study by Herrlinger, K.R., Diculescu, M., Fellermann, K., Hartmann, H., Howaldt, S., Nikolov, R., Petrov, A., Reindl, W., Otte, J.M., Stoynov, S., Strauch, U., Sturm, A., Voiosu, R., Ammendola, A., Dietrich, B., Hentsch, B., Stange, E.F.

“…Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines…”
Get full text

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues by Schmidt, K. J., Müller, N., Dignass, A., Baumgart, D. C., Lehnert, H., Stange, E. F., Herrlinger, K. R., Fellermann, K., Büning, J.

“…Background and aims: Tacrolimus is recommended for the treatment of steroid-refractory ulcerative colitis (UC). Concomitantly started purine analogues (PAs)…”
Get full text

Oral methotrexate in ulcerative colitis by Cummings, J. R. F., Herrlinger, K. R., Travis, S. P. L., Gorard, D. A., McIntyre, A. S., Jewell, D. P.

“…Summary Background : We performed an audit of methotrexate for ulcerative colitis, because efficacy is unclear. Aim : To investigate the role of methotrexate…”
Get full text

Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease by KÜBLER, I., KOSLOWSKI, M. J., GERSEMANN, M., FELLERMANN, K., BEISNER, J., BECKER, S., ROTHFUSS, K., HERRLINGER, K. R., STANGE, E. F., WEHKAMP, J.

“…Summary Background  Crohn’s Disease (CD), a chronic intestinal inflammation, is currently treated primarily by therapeutics which are directed against…”
Get full text

The Religious Landscape of Revolutionary St. Petersburg, 1905-1918 by Herrlinger, K. Page

“…Although legitimately associated with a crisis of faith and the rapid spread of atheistic-socialism, the revolutionary period 1905-1918 in St…”
Get full text

Azathioprine in Crohn's disease therapy--guidance against the background of recent studies by Schmidt, C, Herrlinger, K, Siegmund, B, Bokemeyer, B, Schreiber, S, Stallmach, A

“…Thiopurines (azathioprine and 6-mercaptopurine) are the most frequently used drugs in the treatment of patients with Crohn's disease. In current guidelines…”
Get more information

Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status by Wehkamp, J, Schmidt, K, Herrlinger, K R, Baxmann, S, Behling, S, Wohlschläger, C, Feller, A C, Stange, E F, Fellermann, K

“…Background/Aims: Recent reports have suggested that Helicobacter pylori infection induces the mucosal antibiotic peptide human β defensin 2 (HBD-2). Therefore,…”
Get full text

Review article: interactions between genotype and response to therapy in inflammatory bowel diseases by HERRLINGER, K. R., JEWELL, D. P.

“…Summary Background More than half of the patients with inflammatory bowel diseases are candidates for immunosuppressive therapy. However, even the most…”
Get full text

6‐Thioguanine — efficacy and safety in chronic active Crohn's disease by Herrlinger, K. R., Kreisel, W., Schwab, M., Schoelmerich, J., Fleig, W. E., Ruhl, A., Reinshagen, M., Deibert, P., Fellermann, K., Greinwald, R., Stange, E. F.

“…Summary Background : Azathioprine and mercaptopurine are commonly used in chronic active Crohn's disease. They share the disadvantage of a delayed onset of…”
Get full text

Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission by Herrlinger, K R, Noftz, M K, Dalhoff, K, Ludwig, D, Stange, E F, Fellermann, K

“…Information on the occurrence and frequency of pulmonary involvement in patients with inflammatory bowel disease (IBD) is inconsistent. The aim of this…”
Get full text

Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis — A need for prophylaxis by Escher, M., Stange, E.F., Herrlinger, K.R.

“…Here we report 2 cases of fatal Pneumocystis jirovecii pneumonia in patients with severe ulcerative colitis receiving combination immunosuppression including…”
Get full text

Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011 by Dignass, A, Preiss, J C, Aust, D E, Autschbach, F, Ballauff, A, Barretton, G, Bokemeyer, B, Fichtner-Feigl, S, Hagel, S, Herrlinger, K R, Jantschek, G, Kroesen, A, Kruis, W, Kucharzik, T, Langhorst, J, Reinshagen, M, Rogler, G, Schleiermacher, D, Schmidt, C, Schreiber, S, Schulze, H, Stange, E, Zeitz, M, Hoffmann, J C, Stallmach, A

Get more information

Innate immunity and colonic inflammation: Enhanced expression of epithelial α-defensins by WEHKAMP, J, SCHWIND, B, HERRLINGER, K. R, BAXMANN, S, SCHMIDT, K, DUCHROW, M, WOHLSCHLÄGER, C, FELLER, A. C, STANGE, E. F, FELLERMANN, K

“…Human alpha-defensins contribute to local intestinal host defense as part of innate immunity and may be of major relevance in microbial infection and chronic…”
Get full text

Remission maintenance by tioguanine in chronic active Crohn's disease by Herrlinger, K. R., Deibert, P., Schwab, M., Kreisel, W., Fischer, C., Fellermann, K., Stange, E. F.

“…Summary Background: Tioguanine may offer an alternative for immunosuppression in chronic active Crohn's disease. Recently, we have shown that tioguanine is…”
Get full text

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 Versus prednisolone in active crohn's disease by HERRLINGER, Klaus R, WITTHOEFT, Thomas, SCHWERTSCHLAG, Ulrich, SHAPIRO, Mark, STANGE, Eduard F, RAEDLER, Andreas, BOKEMEYER, Bernd, KRUMMENERL, Thomas, SCHULZKE, Jorg-Dieter, BOERNER, Norbert, KUEPPERS, Bruno, EMMRICH, Joerg, MESCHEDER, Axel

“…Interleukin-11 has shown benefit in animal inflammatory bowel disease models. Recently, recombinant human interleukin-11 (rhIL-11) has been observed to induce…”
Get full text

Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5‐ASA use by Herrlinger, K. R., Noftz, M. K., Fellermann, K., Schmidt, K., Steinhoff, J., Stange, E. F.

“…Background: Conflicting data exist about proteinuria in inflammatory bowel diseases. It is still unclear whether the occurrence of proteinuria in inflammatory…”
Get full text